Corcept Therapeutics Incorporated (CORT)
- Previous Close
69.27 - Open
69.22 - Bid 70.89 x 100
- Ask 72.18 x 100
- Day's Range
69.16 - 71.58 - 52 Week Range
22.00 - 117.33 - Volume
215,959 - Avg. Volume
1,556,600 - Market Cap (intraday)
7.549B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
58.17 - EPS (TTM)
1.23 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
143.25
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
www.corcept.comRecent News: CORT
View MorePerformance Overview: CORT
Trailing total returns as of 4/24/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
View MoreValuation Measures
Market Cap
7.31B
Enterprise Value
6.93B
Trailing P/E
56.32
Forward P/E
42.02
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.64
Price/Book (mrq)
10.75
Enterprise Value/Revenue
10.27
Enterprise Value/EBITDA
50.13
Financial Highlights
Profitability and Income Statement
Profit Margin
20.92%
Return on Assets (ttm)
11.71%
Return on Equity (ttm)
23.81%
Revenue (ttm)
675.04M
Net Income Avi to Common (ttm)
139.73M
Diluted EPS (ttm)
1.23
Balance Sheet and Cash Flow
Total Cash (mrq)
383.33M
Total Debt/Equity (mrq)
1.02%
Levered Free Cash Flow (ttm)
183.85M